Our drug development approach focuses on identifying and advancing small molecules designed to achieve clinically translatable endpoints for neuroscience, inflammation and immunology (NI&I) indications with high unmet need. We are focused on targeting biological pathways associated with specific clinical disabilities, that once modulated, will demonstrably impact the course of disease.
We have a pipeline of internally-developed programs to address multiple NI&I disorders, including PIPE-791, an LPA1 receptor antagonist, in Phase 1 for idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (PMS), and PIPE-307, a selective inhibitor of the M1 receptor in Phase 2 for relapse-remitting multiple sclerosis (RRMS) and a Phase 2 for depression planned to initiate in mid-2024. Contineum is developing PIPE-307 in collaboration with Johnson & Johnson Innovative Medicines (J&J). In addition, we are advancing discovery efforts targeting other NI&I indications where the Company’s internally-discovered molecules and approach may have therapeutic potential.